CYP19A1 and breast carcinoma: The SOLAR-1 randomized, phase 3 trial combined the PI3K inhibitor alpelisib with fulvestrant in patients with PIK3CA-mutant HR+ HER2– breast cancer [20] and the FAKTION trial combined the oral AKT inhibitor capivasertib with fulvestrant after relapse or progression on an aromatase inhibitor [26].